Arrowhead Pharmaceuticals (ARWR) Minority Interest (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 16 years of Minority Interest data on file, last reported at -$15.1 million in Q1 2026.

• Quarterly Minority Interest fell 1766.04% year-over-year to -$15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.1 million (down 1766.04% YoY) and the FY2025 annual result came in at $37.4 million, up 564.96% from the prior year.
• Minority Interest eased to -$15.1 million in Q1 2026, from -$5.7 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $37.4 million in Q3 2025 to a low of -$15.1 million in Q1 2026.
• A 5-year average of $10.5 million and a median of $12.5 million in 2023 frame the typical range for Minority Interest.
• Annual changes were most pronounced in 2025 — Minority Interest soared 564.96% — and 2026, when it sank 1766.04%.
• Tracing ARWR's Minority Interest over 5 years: stood at $19.3 million in 2022, then sank by 31.17% to $13.3 million in 2023, then slumped by 73.8% to $3.5 million in 2024, then sank by 264.23% to -$5.7 million in 2025, then tumbled by 163.07% to -$15.1 million in 2026.
• The last three Minority Interest figures came in at -$15.1 million (Q1 2026), -$5.7 million (Q4 2025), and $37.4 million (Q3 2025), per Business Quant data.